Technical Analysis for ALDX - Aldeyra Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical ALDX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| 20 DMA Resistance | Bearish | -1.53% | |
| 50 DMA Resistance | Bearish | -1.53% | |
| MACD Bearish Signal Line Cross | Bearish | 1.85% | |
| Down 3 Days in a Row | Weakness | 1.85% | |
| Fell Below 20 DMA | Bearish | -1.20% | |
| Fell Below 50 DMA | Bearish | -1.20% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -3.90% | |
| Overbought Stochastic | Strength | -3.90% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 3% | about 20 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| 10 DMA Resistance | about 21 hours ago |
| Down 2 % | about 21 hours ago |
| 50 DMA Resistance | about 21 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2020
Aldeyra Therapeutics, Inc. (Aldeyra) is a biotechnology company. The Company is focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be related to a naturally occurring toxic chemical species known as free aldehydes. The Company is developing NS2. NS2 is a product candidate that is designed to trap and allow for disposal of free aldehydes, for the treatment of diseases, which include Sjogren-Larsson Syndrome (SLS), discoid lupus, acute anterior uveitis and ocular rosacea with meibomian gland dysfunction. Aldeyra is also developing aldehyde traps distinct from NS2. As of April 7, 2014, it had evaluated NS2 in a Phase I clinical trial in 48 volunteers.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Diseases Organ Systems Autoimmune Diseases Rare Diseases Dysfunction Syndromes Lupus Rosacea Uveitis Inflammatory Discoid Lupus Meibomian Gland Ns2 Systemic Lupus Erythematosus
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Diseases Organ Systems Autoimmune Diseases Rare Diseases Dysfunction Syndromes Lupus Rosacea Uveitis Inflammatory Discoid Lupus Meibomian Gland Ns2 Systemic Lupus Erythematosus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.6178 |
| 52 Week Low | 2.5 |
| Average Volume | 826,567 |
| 200-Day Moving Average | 8.45 |
| 50-Day Moving Average | 11.97 |
| 20-Day Moving Average | 11.75 |
| 10-Day Moving Average | 12.08 |
| Average True Range | 0.79 |
| ADX | 12.83 |
| +DI | 17.69 |
| -DI | 22.02 |
| Chandelier Exit (Long, 3 ATRs ) | 10.48 |
| Chandelier Exit (Short, 3 ATRs ) | 12.49 |
| Upper Bollinger Band | 12.93 |
| Lower Bollinger Band | 10.58 |
| Percent B (%b) | 0.42 |
| BandWidth | 19.95 |
| MACD Line | 0.01 |
| MACD Signal Line | 0.06 |
| MACD Histogram | -0.0429 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.62 | ||||
| Resistance 3 (R3) | 12.68 | 12.38 | 12.45 | ||
| Resistance 2 (R2) | 12.38 | 12.12 | 12.36 | 12.39 | |
| Resistance 1 (R1) | 11.98 | 11.95 | 11.83 | 11.92 | 12.33 |
| Pivot Point | 11.68 | 11.68 | 11.61 | 11.66 | 11.68 |
| Support 1 (S1) | 11.28 | 11.42 | 11.13 | 11.22 | 10.81 |
| Support 2 (S2) | 10.98 | 11.25 | 10.96 | 10.75 | |
| Support 3 (S3) | 10.58 | 10.98 | 10.70 | ||
| Support 4 (S4) | 10.52 |
